Medicare Enrolled

Dr. Danai Dima, MD

Hematology & Oncology · Seattle, WA
Low-engagement
825 EASTLAKE AVE E, Seattle, WA 98109
2065205000
In practice since 2018 (8 years)
NPI: 1790270247 verify on NPPES ↗
Moderate
DATA COVERAGE
Data in 3 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Dima from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Dima? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Dima

Dr. Danai Dima is a hematology & oncology specialist in Seattle, WA, with 8 years of NPI registration.

Between the years covered by Open Payments, Dr. Dima received a total of $4,196 from 19 pharmaceutical and/or device companies across 47 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Dima is Moderate — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 8 years in practice $4,196 industry payments

Industry Payment Transparency

Open Payments through 2024 ↗
$4,196
Total received (2019-2024)
Avg $839/year across 5 years
Top 31% in WA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
19
Companies
47
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,795 (66.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,400 (33.4%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$900
2023
$1,373
2022
$1,104
2021
$523
2019
$296

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$360
Stemline Therapeutics Inc.
$140
Incyte Corporation
$121
Gilead Sciences, Inc.
$116
Novartis Pharmaceuticals Corporation
$106
Janssen Biotech, Inc.
$58
Top 3 companies account for 68.9% of 2024 payments
All-time payments by company (2019-2024) ›
Incyte Corporation
$827
Seagen Inc.
$627
PFIZER INC.
$360
Astellas Pharma US Inc
$322
SANOFI-AVENTIS U.S. LLC
$286
Novartis Pharmaceuticals Corporation
$257
E.R. Squibb & Sons, L.L.C.
$247
Alexion Pharmaceuticals, Inc.
$198
Janssen Biotech, Inc.
$157
Stemline Therapeutics Inc.
$140
Daiichi Sankyo Inc.
$127
Amgen Inc.
$120
Gilead Sciences, Inc.
$116
JAZZ PHARMACEUTICALS INC.
$114
Foundation Medicine, Inc.
$96
Takeda Pharmaceuticals U.S.A., Inc.
$89
Lilly USA, LLC
$77
Janssen Scientific Affairs, LLC
$22
BTG International, Inc.
$15
Top 3 companies account for 43.2% of all-time payments
Associated products mentioned in payments ›
CARVYKTI · ELITEK · FOUNDATIONONE · Fabhalta · JAKAFI · JEVTANA · KYMRIAH · MONJUVI · OPDIVO · Orserdu · PADCEV · SCEMBLIX · TECVAYLI · TUKYSA · Trodelvy · ULTOMIRIS · VORAXAZE · VYXEOS · XTANDI
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (67%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a hematology & oncology specialist in Seattle?
Compare hematology & oncology specialists in the Seattle area by procedure volume, costs, and industry payment transparency.
Browse hematology & oncology specialists nearby

Geographic Context

Hematology & oncology specialists within 10 mi
268
Per 100K population
11.8
County median income
$122,148
Nearest hospital
VIRGINIA MASON MEDICAL CENTER
1.4 mi

Data Sources

Provider Registry ✓ NPPES Weekly updates
Medicare Enrollment ✓ PECOS Monthly updates
Practice Data — No data N/A
Industry Payments ✓ Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 3 of 4 available federal datasets, with a Data Coverage level of Moderate. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Dima is a hematology & oncology specialist, with low-engagement industry engagement.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Does Dr. Dima receive payments from pharmaceutical companies?
Yes. Dr. Dima received a total of $4,196 from 19 companies across 47 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
What does Data Coverage mean?
Data Coverage (currently Moderate for Dr. Dima) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →

Explore related providers

Same specialty & city
Hematology & Oncology Specialists in Seattle
Browse hematology & oncology specialists in Seattle ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in WA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in WA
Which WA hematology & oncology specialists receive the most from drug and device companies.
By company
Incyte Corporation Payments to Doctors
See all physicians who received payments from Incyte Corporation.
By company
Seagen Inc. Payments to Doctors
See all physicians who received payments from Seagen Inc.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →